This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.
Tandem Diabetes' Sugarmate Buyout Boosts Digital Offerings
by Zacks Equity Research
Tandem Diabetes (TNDM) expands digital portfolio with the Sugarmate app buyout, paving the way for the company's expansion of diabetes-related products and services ecosystem.
Tandem Diabetes Gets Expanded Indication for Insulin Pump
by Zacks Equity Research
Tandem Diabetes (TNDM) receives clearance for expanded indication for pediatric use of t:slim X2 insulin pump with Control-IQ, paving the way for simpler diabetes management in younger patient pool.
Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
by Zacks Equity Research
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Here's Why You Should Add Tandem Diabetes to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off
by Zacks Equity Research
This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.
Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ
by Urmimala Biswas
Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.
Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.
Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences
by Zacks Equity Research
Zacks.com featured highlights include: International Money Express, Tandem Diabetes Care, Kirkland Lake Gold and USANA Health Sciences
4 Best-Ranked Liquid Stocks for Alluring Returns
by Zacks Equity Research
Four top-ranked liquid stocks that investors can bank on for fat returns.
Should You Buy Tandem Diabetes Care (TNDM) Ahead of Earnings?
by Zacks Equity Research
Tandem Diabetes Care (TNDM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.
5 Top-Ranked Stocks Beating the Market at Midway Q1
by Sweta Killa
Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.
5 High-Flying Stocks Set to Beat on Q4 Earnings Next Week
by Nalak Das
Fourth-quarter 2019 earnings results have been improving significantly.
What's in Store for SmileDirectClub's (SDC) Q4 Earnings?
by Zacks Equity Research
SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.
Tandem Diabetes Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.
Are Options Traders Betting on a Big Move in Tandem Diabetes (TNDM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.